Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;54(7):671-679.
doi: 10.1055/a-1708-0037. Epub 2022 Feb 4.

Endoscopic ultrasound-guided gastroenterostomy versus surgical gastrojejunostomy for the palliation of gastric outlet obstruction in patients with peritoneal carcinomatosis

Affiliations

Endoscopic ultrasound-guided gastroenterostomy versus surgical gastrojejunostomy for the palliation of gastric outlet obstruction in patients with peritoneal carcinomatosis

Ali Abbas et al. Endoscopy. 2022 Jul.

Abstract

BACKGROUND : Gastric outlet obstruction (GOO) with peritoneal carcinomatosis presents a technical challenge. Surgical gastrojejunostomy (SGJ) or enteral stenting have been the standard of care; however, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has emerged as a favorable alternative. Few data exist that compare these techniques in the setting of peritoneal carcinomatosis. METHODS : This single-center retrospective cohort study included 25 EUS-GE and 27 SGJ consecutive patients. Baseline demographics, cancer diagnosis and stage, clinical and technical success, adverse events, and obstruction recurrence data were collected. The primary outcome was the technical success comparison; secondary outcome was the adverse event rate comparison. Rates were compared with standard statistical tests. RESULTS : Mean age, obstruction location, and symptoms were similar between the groups. The EUS-GE group had more advanced disease (clinical stage 4, 100 % vs. 67 %; P = 0.006) and higher American Society of Anesthesiologists classification (class 3-4, 92 % vs. 50 %; P = 0.004). The technical success rate was 100 % in both groups (P > 0.99) and the adverse event rate was lower for EUS-GE (8 % vs. 41 %; P = 0.01). Clinical success was 88 % for EUS-GE and 85 % for SGJ (P > 0.99) and recurrent obstruction was lower with EUS-GE (28 % vs. 41 %; P = 0.13). The EUS-GE group had shorter procedure duration, length of stay, and time to chemotherapy resumption than the SGJ group. CONCLUSIONS : Although the EUS-GE group was older, with more comorbidity and advanced stages, the technical success rate was similar to SGJ and it had significantly fewer adverse events. EUS-GE is a safe and effective option for the management of malignant GOO with peritoneal carcinomatosis.

PubMed Disclaimer

Conflict of interest statement

C.C. Thompson: Apollo Endosurgery – Consultant/Research Support (Consulting fees/Institutional Research Grants); Aspire Bariatrics – Research Support (Institutional Research Grant); BlueFlame Healthcare Venture Fund – General Partner; Boston Scientific – Consultant (Consulting fees)/Research Support (Institutional Research Grant); Covidien/ Medtronic – Consultant (Consulting Fees); EnVision Endoscopy – Board Member; Fractyl – Consultant/Advisory Board Member (Consulting Fees); GI Dynamics – Consultant (Consulting Fees)/ Research Support (Institutional Research Grant); GI Windows – Ownership interest Lumendi – Consultant; Olympus/Spiration – Consultant (Consulting Fees)/Research Support (Equipment Loans); Spatz – Research Support (Institutional Research Grant); USGI Medical – Consultant (Consulting Fees)/Advisory Board Member (Consulting fees)/Research Support (Research Grant); Fujifilm – Consultant (Consulting Fees)/Institutional Research Grant; ERBE – Institutional Research Grant. R.D. Dolan, A. Abbas and A.N. Bazarbashi have no personal or financial conflicts of interest to disclose.

MeSH terms